NKGN VS MRK Stock Comparison

PerformanceVolatilityAnalyst Price TargetsTechnicalsEarningsProfitDividend
PerformanceVolatilityAnalyst Price TargetsTechnicalsEarningsProfitDividend

Performance

NKGN
10/100

NKGN returned -53.87% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

MRK
100/100

MRK returned 1.78% in the last 12 months. Based on SPY's performance of -13.80%, its performance is above average giving it a score of 100 of 100.

Volatility

NKGN
10/100

NKGN has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.

MRK
52/100

MRK has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Analyst Price Targets

NKGN

"Analyst Price Targets" not found for NKGN

MRK
68/100

21 analysts offer 12-month price targets for MRK. Together, they have an average target of 113.88, the most optimistic target put MRK at 294 within 12-months and the most pessimistic has MRK at 80.

Technicals

NKGN

"Technicals" not found for NKGN

MRK
10/100

MRK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

NKGN

"Earnings" not found for NKGN

MRK
53/100

MRK has missed earnings 3 times in the last 20 quarters.

Profit

NKGN

"Profit" not found for NKGN

MRK
66/100

Out of the last 20 quarters, MRK has had 17 profitable quarters and has increased their profits year over year on 7 of them.

Dividend

NKGN

"Dividend" not found for NKGN

MRK
100/100

MRK's most recent dividend was $0.47 per share, based on a share price of $101.35. It was a payout ratio of 69.90% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

NKGen Biotech, Inc. Common Stock Summary

Nasdaq / NKGN
Healthcare
Biotechnology
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.

Merck & Co., Inc. Summary

New York Stock Exchange / MRK
Healthcare
Drug Manufacturers - General
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.